AstraZeneca Steps Up Its Drive In Emerging Markets

BMI View: Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated - BMI's Pharmaceutical Expenditure Model reveals that five-year compound annual growth rates (CAGRs) in traditional markets, such as the US, Western Europe and Japan, are all in the low single figures. Meanwhile, the US dollar five-year CAGRs for the main emerging markets - Brazil, Russia, India and China - are expected to see double-digit increases.

To read the full article, please choose one of the following options: